[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-ischemia-reperfusion-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-ischemia-reperfusion-injury":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100600666","or6a2-on-monocytes-and-cardiovascular-outcomes-in-myocardial-ischemia-reperfusion-injury-100600666",false,"NCT07100457","OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury","Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury","Inclusion Criteria:\n\n1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.\n2. Age 18-90 years inclusive.\n\nExclusion Criteria:\n\n1. Active systemic infections.\n2. Advanced heart failure (NYHA class III-IV).\n3. Acute cerebrovascular conditions.\n4. Active myocarditis.\n5. cardiomyopathy.\n6. Refractory ventricular tachycardia\u002Ffibrillation.\n7. Diagnosis\u002Fconcurrent treatment for malignancy within 5 years (except non-melanoma skin cancer\u002Fcarcinoma in situ).\n8. Severe renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73m2 or dialysis dependence).\n9. Child-Pugh class C hepatic dysfunction.","ALL","18 Years","90 Years",{"count":20,"type":21},200,"ESTIMATED","44 Months","OBSERVATIONAL","This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress\u002Finflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2\u002Foctanal\u002Finflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.",[26],"Myocardial Ischemia-Reperfusion Injury","RECRUITING","2025-07-30",{"date":30,"type":31},"2025-08-03","ACTUAL",{"date":33,"type":31},"2019-09-01",{"date":35,"type":21},"2027-08-30",{"name":37,"class":38},"Southeast University, China","OTHER"]